HIF1A and COVID-19: Thus, if the prediction of Codo et al. [64] is valid, which we feel it is, the inhibition of HIF-1α would contribute to a reduction in lung damage and COVID-19 severity, then the use of melatonin as a treatment of SARS-CoV-2-infected patients would be further justified [70–72].